Yu Zhou | Manager, Analytical Development, Viral Vector for Cell and Gene Therapy
Millipore Sigma | United States

Dr. Yu Zhou is a highly skilled Manager in Analytical Development specializing in viral vectors for cell and gene therapy as well as oncolytic virotherapy within the Life Science division at Millipore Sigma. Prior to joining Millipore Sigma, she spent six years at Novartis, focusing on gene and cell therapy development, and 5.5 years at BioMarin Pharmaceutical, where she concentrated on gene therapy and enzyme replacement therapy development. Her experience also includes roles at Abbott/AbbVie and Waters Corporation. Dr. Zhou holds a PhD in Pharmaceutical Science and possesses over 18 years of experience in the pharmaceutical industry, with expertise in the characterization, method development, qualification, and transfer of biotherapeutics, including monoclonal antibodies, recombinant enzymes, gene and cell therapy products, and oncolytic virotherapies. She is passionate about advancing biotherapeutics, gene and cell therapies, and oncolytic virotherapies. Dr. Zhou has contributed to the commercialization of AAV-based gene therapy product, Roctavian (AAV5) by BioMarin Pharmaceutical, and worked on Zolgensma (AAV9) by Novartis. Dr. Zhou's unique blend of technical expertise, leadership skills, and industry knowledge makes her a valuable asset in the biopharmaceutical sector, driving advancements in viral vector analytics and facilitating the successful translation of cell and gene therapies and oncolytic virotherapies from discovery to market.